NCT03946488

Brief Summary

Stroke is the leading cause of disability in adults. The improvement of the grasp abilities remains a challenge in the 50% of post-stroke subjects who have not recovered functional grasping due to paralysis of the finger's muscles (lack of active opening of the hand). The use of functional electrical stimulation of the prehension muscles in order to restore grasp abilities, called grasp neuroprosthesis (GP), remained confidential in post-stroke subjects while their development was important in tetraplegic subjects. GP can provide a correct hand opening with significant functional gain, but one of the major issues corresponds to the control modalities that are not adapted to the specific impairments of post-stroke subjects. This project proposes to assess the functional contribution of an innovative autopilot closed-loop GP targeting the extensor muscles of the fingers. The main hypothesis is that the use of GP will restore grasping abilities in subjects who have lost this ability due to post-stroke paralysis. The main objective is to assess the impact of using an autopilot closed-loop GP on the ability to perform a standardized task of grasping, moving and releasing either a glass (palmar grasp) or a spoon (key pinch), compared to the absence of GP use. The secondary objectives of the study are: (1) to assess the impact of the GP on unimanual grasp; (2) to assess which are the preferential modes of control; (3) to assess the psycho-social impacts of GP, and (4) to assess the subject's satisfaction and tolerance to the characteristics and use of GP. The investigators plan to include 20 post-stroke hemiplegic subjects over a period of 9 months as part of a prospective, monocentric, multi-crossover, blinded evaluation study. Subjects will have active finger extension deficit secondary to stroke, with preservation of proximal movements. Each subject will be his own control (self-pairing). Each subject will be evaluated three times, the protocol adding approximately 1½ hours of daily assessment to routine care already received. The first visit will collect clinical data after informed consent collection. The second visit will allow to choose the optimal mode of control of the GP among 8 modalities. The third visit will test the functional gain provided by the use of GP, by comparing the success or failure of carrying out functional tasks with inactive and active GP.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for not_applicable stroke

Timeline
Completed

Started Jul 2019

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 24, 2019

Completed
16 days until next milestone

First Posted

Study publicly available on registry

May 10, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

July 9, 2019

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 6, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 6, 2021

Completed
Last Updated

December 4, 2025

Status Verified

July 1, 2021

Enrollment Period

1.5 years

First QC Date

April 24, 2019

Last Update Submit

November 26, 2025

Conditions

Keywords

Hand function restorationPrehensionClosed-loop controlled neuroprosthesis

Outcome Measures

Primary Outcomes (1)

  • Rate of success of the main functional task

    The main functional task consist of grasping, moving and releasing either a glass (palmar grasp) or a spoon (key grip): the task (palmar grasp or key grip) preferred by the patient will be chosen. The assessment will consist of 24 trials with the active or inactive neuroprosthesis (12 activated and 12 inactivated), the order of the trials with / without neuroprosthesis being randomized in blocks of at least three trials. In order to limit the fatigue potentially induced by the repetition of stimulations, a pause between each trial will be respected if necessary. The maximum time allowed for the completion of each test will be 1 minute. A success corresponds to a complete completion of the functional task in at least 2/3 of the trials (i.e. 8/12 trials) with the activated neuroprosthesis. The success / failure score will be assessed secondarily from video recordings by a blind evaluator of the activation or not of the neuroprosthesis.

    Third day

Secondary Outcomes (4)

  • Rate of success of the secondary functional task

    Third day

  • Comparison of the Action Research Arm Test (ARAT) performed with the inactivated (first day) and activated (day three) neuroprosthesis

    First and third day

  • Psychosocial Impact of Assistive Devices (PIADS) questionnaire

    Third day

  • Subscale "Device" from the questionnaire Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST)

    Third day

Study Arms (2)

Inactive neuroprosthesis

NO INTERVENTION

Active neuroprosthesis

EXPERIMENTAL
Device: Functional electrical stimulation

Interventions

Functional electrical stimulation of finger's muscles in order to open the hand

Active neuroprosthesis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The patient must have given free and informed consent and signed the consent;
  • The patient must be an affiliate or a beneficiary of a health insurance plan;
  • The patient is hospitalized as part of routine care and available for at least 3 consecutive days of follow-up during hospitalization;
  • Motor deficiency of the upper limb due to a hemorrhagic or ischemic stroke;
  • Stroke more than one months old;
  • Inability to perform an active extension of the long fingers (opening of the hand) to voluntarily seize an empty glass with a palmar grip (grasping task in the ARAT scale), while the subject can hold the previously placed glass passively in the hand; and / or
  • Inability to perform an active thumb extension to voluntarily grasp the handle of a tablespoon (flat, like a key) with a pulpo-lateral thumb-index or key-grip (grasping task in the Wolf Motor Function Scale Test), while the subject can hold the spoon previously placed passively between thumb and index;
  • Ability to sit on a chair for at least 2 hours.

You may not qualify if:

  • The subject participates in another interventional study;
  • The subject is under the protection of justice, guardianship or curatorship;
  • The subject refuses to sign or give consent;
  • It is not possible to give the subject enlightened information.
  • The patient is pregnant, parturient, or breastfeeding;
  • Patient with pacemaker;
  • Unstable epilepsy;
  • Unstable cardiovascular pathology (coronary heart disease, major hypertension, heart failure);
  • Dermatological problems counter-indicating the application of surface electrodes;
  • Musculotendinous retractions or joint stiffness of the fingers and wrist preventing passive opening of the hand sufficient to perform the functional tasks evaluated;
  • Active elbow extension limited to not reaching the ipsilateral knee, the subject sitting (limitation of the approach);
  • Upper limb pain limiting movements;
  • Major sensory disorders corresponding to a score of the Modified Erasmus Nottingham Sensory Assessment English version of the upper limb \<10/44;
  • Severe aphasia with aphasia severity scale of the Boston Diagnostic Severity Aphasia Examination \<= 3, indicating that there may be a clear decrease in verbal fluency or ease and speed of understanding, with no significant limitation expression or communication;
  • Unilateral spatial negligence highlighted with the bell test if the difference between omissions in the left and right fields is greater than or equal to 6;
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CHU de Nîmes

Nîmes, France

Location

CHU de TOULOUSE

Toulouse, 31400, France

Location

Related Publications (1)

  • Le Guillou R, Froger J, Morin M, Couderc M, Cormier C, Azevedo-Coste C, Gasq D. Specifications and functional impact of a self-triggered grasp neuroprosthesis developed to restore prehension in hemiparetic post-stroke subjects. Biomed Eng Online. 2024 Dec 21;23(1):129. doi: 10.1186/s12938-024-01323-y.

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Christine Azevedo, PhD

    Institut National de Recherche en Informatique et en Automatique

    STUDY CHAIR
  • Jérôme Froger, MD

    Centre Hospitalier Universitaire de Nīmes

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 24, 2019

First Posted

May 10, 2019

Study Start

July 9, 2019

Primary Completion

January 6, 2021

Study Completion

January 6, 2021

Last Updated

December 4, 2025

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share

Locations